| __timestamp | Dynavax Technologies Corporation | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 17763000 | 381287000 |
| Thursday, January 1, 2015 | 22180000 | 452612000 |
| Friday, January 1, 2016 | 37257000 | 316800000 |
| Sunday, January 1, 2017 | 27367000 | 330100000 |
| Monday, January 1, 2018 | 64770000 | 265800000 |
| Tuesday, January 1, 2019 | 74986000 | 336200000 |
| Wednesday, January 1, 2020 | 79256000 | 423900000 |
| Friday, January 1, 2021 | 100156000 | 467000000 |
| Saturday, January 1, 2022 | 131408000 | 487000000 |
| Sunday, January 1, 2023 | 152946000 | 477100000 |
Unleashing the power of data
In the competitive world of biotechnology, operational efficiency is key. This analysis compares the Selling, General, and Administrative (SG&A) expenses of United Therapeutics Corporation and Dynavax Technologies Corporation from 2014 to 2023. Over this period, United Therapeutics consistently outspent Dynavax, with SG&A expenses peaking at approximately 487% higher in 2022. This trend highlights United Therapeutics' aggressive investment in operational activities, possibly reflecting its larger market presence and broader product portfolio. Meanwhile, Dynavax's SG&A expenses grew significantly, increasing by over 760% from 2014 to 2023, indicating a strategic push towards expansion. Understanding these financial dynamics offers insights into each company's strategic priorities and market positioning. As the biotech industry evolves, monitoring such financial metrics will be crucial for investors and stakeholders aiming to gauge company performance and future potential.
Who Optimizes SG&A Costs Better? AstraZeneca PLC or Dynavax Technologies Corporation
Gilead Sciences, Inc. vs United Therapeutics Corporation: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Genmab A/S
United Therapeutics Corporation and Bio-Techne Corporation: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Lantheus Holdings, Inc.
SG&A Efficiency Analysis: Comparing United Therapeutics Corporation and Catalyst Pharmaceuticals, Inc.
Comparing SG&A Expenses: United Therapeutics Corporation vs Bausch Health Companies Inc. Trends and Insights
United Therapeutics Corporation vs Vericel Corporation: SG&A Expense Trends
United Therapeutics Corporation vs Xencor, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation
Ligand Pharmaceuticals Incorporated vs Dynavax Technologies Corporation: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Dynavax Technologies Corporation or BioCryst Pharmaceuticals, Inc.